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Anti-neutrophil cytoplasmic antibodies (ANCA) are a group of
auto-antibodies directed against components of neutrophil gran-
ules and monocyte lysosomes. Since the first description of ANCA
by Davies et al in 1982 in patients with segmental necrotizing
glomerulonephritis, ANCA have been demonstrated in a number
of primary vasculitic syndromes [1]. In 1985, van der Woude et al
reported on ANCA as a specific and sensitive marker for active
Wegener’s granulomatosis [2]. ANCA were later shown to be
present in Churg-Strauss syndrome [3, 4], microscopic polyangiitis
[5], and pauci-immune necrotizing crescentic glomerulonephritis
(NCGN) [6, 7]. In most cases of systemic vasculitis, the primary
target antigens for ANCA are proteinase 3 (Pr3), a serine
proteinase, and myeloperoxidase (MPO), an enzyme involved in
the production of reactive oxygen intermediates [6, 8–10]. Both
enzymes are present in secretory granules of neutrophils and
monocytes. Although anti-Pr3 and anti-MPO are found across the
spectrum of ANCA-associated vasculitides, it is now well estab-
lished that anti-Pr3 is a sensitive marker for Wegener’s granulo-
matosus whereas anti-MPO is predominantly found in micro-
scopic polyangiitis, pauci-immune NCGN, and Churg-Strauss
syndrome [11]. Although not uniformly accepted, changes in titers
of ANCA seem to reflect changes in disease activity [12–16].
Besides being a helpful diagnostic tool, their strong association
with primary vasculitic syndromes suggests an important role for
ANCA in the pathophysiology of the associated diseases. Exper-
imental evidence for the pathogenic potential of ANCA has been
derived mainly from in vitro studies. These studies have provided
a wealth of information on the interaction of ANCA with their
target antigens and their capacity to activate neutrophils and/or
monocytes. The relevance of these in vitro phenomena for the
pathophysiology of ANCA-associated systemic vasculitides is,
however, far from clear. Experimental research on ANCA-asso-
ciated vasculitis clearly needs satisfactory animal models [17]. In
recent years, several animal studies have been reported on ANCA
and vasculitis using various experimental approaches. The present
article reviews these studies and evaluates their implications for
the pathogenesis of ANCA-associated systemic vasculitis. First, a
brief overview will be given on experimental in vitro data substan-
tiating a pathophysiological role for ANCA.
A PATHOPHYSIOLOGICAL ROLE FOR ANCA: IN VITRO
STUDIES
ANCA-mediated neutrophil activation
In 1990, Falk et al showed that ANCA can activate tumor
necrosis factor alpha (TNFa) primed neutrophils leading to the
production of reactive oxygen metabolites and the release of
lysosomal proteolytic enzymes, including the ANCA antigens
themselves [18]. As such, ANCA-mediated neutrophil activation
may be directly cytotoxic for target cells [19]. It has indeed been
demonstrated that ANCA promote the adhesion of neutrophils to
endothelial cells and activate primed neutrophils to induce endo-
thelial cell detachment and lysis [20–23].
Although it is currently widely accepted that ANCA are capable
of activating cytokine primed neutrophils, it has also been recog-
nized that the degree of ANCA-mediated production of reactive
oxygen intermediates (ROI) and degranulation is generally mod-
est and variable. Recently, however, ANCA-induced ROI produc-
tion and degranulation was found markedly enhanced in the
presence of extracellular arachidonic acid [24]. It appeared that
ANCA are strong activators of the 59-lipoxygenase pathway in
neutrophils inducing the production of large amounts of leuko-
triene B4. Leukotriene B4 is a potent chemoattractant for neu-
trophils and triggers an autocrine loop of cell activation resulting
in increased ROI production and degranulation. These studies
suggest that at inflammatory sites, where substantial amounts of
arachidonic acid are present, ANCA induce full-blown neutrophil
activation leading to vessel wall necrosis.
In addition to ROI production and degranulation, ANCA also
stimulate neutrophils to secrete cytokines such as interleukin
(IL)-1b [25, 26]. In idiopathic systemic vasculitis, early blood-
vessel lesions are rich in neutrophils but over time a mononuclear
infiltrate predominates [27]. Cytokine production by ANCA-
stimulated neutrophils could contribute to this transition of acute
to chronic inflammation [28].
The mechanisms involved in ANCA-mediated neutrophil acti-
vation are not completely clear. Upon priming with TNFa,
neutrophils express the ANCA antigens on the cell membrane,
Key words: vasculitis, ANCA associated vasculitis, neutrophil activation by
ANCA, monocytes and ANCA.
Received for publication May 30, 1997
and in revised form August 21, 1997
Accepted for publication August 22, 1997
© 1998 by the International Society of Nephrology
Kidney International, Vol. 53 (1998), pp. 253–263
253
which then become accessible for interaction with ANCA [18, 29].
In addition, the ANCA antigens are also expressed on the cell
surface of apoptotic non-primed neutrophils and recognized by
ANCA [30]. Binding of ANCA to primed or apoptotic neutrophils
may lead to further activation of the same or a second neutrophil
that appears to depend largely on the interaction of the Fc portion
of the antibody with FcgRIIa receptors on the neutrophil [31–33].
In some studies F(ab)2 fragments of the antibodies also induced
neutrophil activation, suggesting that FcgR independent pro-
cesses are involved as well [18, 34, 35]. In addition, ANCA-
mediated neutrophil activation does not occur when adhesion of
neutrophils is prevented by either continuous stirring of the cell
suspension or addition of anti-CD18 antibodies [33]. This suggests
that engagement of b2 integrins is also required for neutrophil
activation induced by ANCA [33].
The cytokine dependency of ANCA-mediated neutrophil acti-
vation in vitro corresponds with clinical observations. In clinically
quiescent patients, high ANCA titers can persist, suggesting that
ANCA alone are not sufficient to induce disease activity [13–16].
Furthermore, exacerbations of disease activity are preceded by
infections in many patients and an increased incidence of ANCA-
associated vasculitis is noted during winter months [36, 37]. Also,
nasal carriage of Staphylococcus aureus is an important risk factor
for relapses of Wegener’s granulomatosis [38]. Interestingly, it has
been shown that, during active disease and relapses, circulating
neutrophils of Wegener’s granulomatosis patients express Pr3 and
MPO on their cell surface, in conjunction with other activation
markers [29, 39]. These observations support the hypothesis that
nonspecific activation leading to cytokine production and priming
of neutrophils is required for the onset of disease activity in vivo.
ANCA-mediated monocyte activation
Since the ANCA antigens Pr3 and MPO are constituents of
granules from monocytes, these cells are likely to be targets for
ANCA as well. However, the effects of ANCA on monocytes have
not been studied extensively. It has been reported that monocytes
can be activated by ANCA to produce ROI [40]. This effect was
not dependent on priming with TNFa, although priming did
enhance ANCA-mediated ROI production by monocytes. In
contrast to neutrophils, endothelial cell lysis is not observed in the
presence of ANCA-activated monocytes. ANCA stimulate mono-
cytes to produce monocyte chemoattractant protein-1 [41], which
in vivo could play an important role in the formation of granulo-
mas by amplification of local monocyte recruitment. As FACS
analysis of circulating monocytes of Wegener’s granulomatosis
patients showed, the presence of MPO and Pr3 on the cell surface
during active disease and monocytes express the FcgRIIa receptor
[39], the mechanisms underlying ANCA-induced monocyte acti-
vation are probably similar to those observed for neutrophils.
Interaction between ANCA and endothelial cells
Myeloperoxydase and Pr3 are cationic proteins with isoelectric
points of . 11 and 9.1, respectively. Upon release from ANCA-
activated neutrophils these enzymes can bind to anionic structures
such as basal membranes or the luminal surface of endothelial
cells. Subsequently, in situ binding of ANCA can occur resulting in
complement activation, enhanced influx of inflammatory cells and
antibody-dependent cellular cytotoxicity (ADCC). Activation of
such effector pathways in vivo aggravates the inflammatory pro-
cess and may eventually cause vessel wall destruction. In vitro
studies have shown that ANCA bind to endothelial cells previ-
ously incubated with MPO or Pr3 and induce complement-
dependent endothelial cell lysis [21–23, 42]. However, ANCA-
mediated ADCC could not be demonstrated [43].
Myeloperoxidase and Pr3 are considered specific for cells of the
monomyeloid lineage. Recent studies suggest that Pr3 may be
expressed by other cell types as well, including endothelial cells
[44]. In endothelial cells increased Pr3 expression and transloca-
tion of the enzyme to the cell membrane has been observed after
stimulation with either TNFa, interferon gamma (IFNg) or IL-1b
[44]. Addition of anti-Pr3 antibodies in the presence of primed
neutrophils results in lysis of these primed endothelial cells [45,
46]. These observations suggest that Pr3 is available for interac-
tion with ANCA on endothelial cells at inflammatory sites. Other
studies, however, have not been able to demonstrate Pr3 expres-
sion by (cytokine treated) endothelial cells [47]. It should also be
noted that within vascular lesions in ANCA-associated vasculitis
deposits of immunoglobulin are absent or scanty [48–51]. There-
fore, direct or indirect binding of ANCA to endothelial cells as a
pathophysiological mechanism in the development of ANCA-
associated vasculitis has been disputed.
T-cell reactivity in ANCA associated vasculitis
In the acute phase, ANCA-associated vascular injury is charac-
terized by mural and perivascular influx of neutrophils [27]. Upon
the progression of these inflammatory lesions a chronic mononu-
clear infiltrate develops, sometimes presenting as granulomas
containing mononuclear phagocytes and CD41 T-cells [52–54]. In
the absence of immunoglobulin deposits, these observations sug-
gest that T-cell-mediated immunity also contributes to the patho-
physiology ANCA-associated vascular injury [55]. In agreement,
levels of soluble IL-2 receptor are elevated in Wegener’s granu-
lomatosis patients and increase preceding major relapses, provid-
ing indirect evidence for a role of activated T-cells in systemic
vasculitis [56, 57]. Although the target antigens of these putatively
autoreactive T-cells have not been identified, Pr3 and MPO are
likely candidates. Indeed, lymphocytes isolated from Wegener’s
granulomatosis patients proliferate in response to a crude neu-
trophil extract containing Pr3 and MPO [58–60], and Wegener’s
granulomatosis patients respond more frequently and strongly to
Pr3 than controls [60–62]. However, not all Wegener’s granulo-
matosis patients responded to Pr3 in these studies and T-cell
proliferation was also found in healthy controls [30, 61].
Infections and ANCA-associated vasculitis
Circumstantial evidence suggests a role for infections, particu-
larly infections with Staphylococcus aureus, in the pathophysiology
of ANCA-associated vasculitis. As mentioned before, relapses in
disease activity are often preceded by infections, and chronic nasal
carriage of Staphylococcus aureus is an important risk factor for
the development of relapses in Wegener’s granulomatosus [37,
38]. Furthermore, anti-microbial treatment reduces the incidence
of relapses in Wegener’s granulomatosis [63–65]. Infections may
play several roles in ANCA-associated vasculitis. At the site of
infection, inflammatory mediators such as TNFa are released
inducing activation of the endothelium and priming of PMNs. As
such, infections may be the trigger for ANCA-mediated PMN
activation. Furthermore, cell-wall components of Staphylococcus
aureus are effective, T-cell independent B-cell mitogens that can
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induce autoreactive B-cells to produce ANCA [66–69]. In addi-
tion, microbial antigens may act as superantigens, which in a
non-antigen specific manner cause selective expansion of T-cells
bearing particular T-cell receptor Vb chain variable regions. Thus
far, studies in ANCA-associated vasculitis on the selective use of
the T-cell receptor repertoire have been inconclusive. One study
reported abnormal expansions of T cells, especially CD41 T-cells,
using particular Va and Vb gene products [70], whereas another
study mentioned increased Vb 2.1 gene usage in vasculitis patients
that was most marked in microscopic polyangiitis [71].
Interaction of ANCA with their target antigens
Besides their capacity to activate neutrophils, ANCA also can
affect the enzymatic properties of their target antigens. This has
been demonstrated especially for anti-Pr3 ANCA. Binding of
anti-Pr3 to Pr3 inhibits the irreversible inactivation of Pr3 by
a1-antitrypsin, although most anti-Pr3 positive sera also inhibit
the enzymatic activity of Pr3 [72, 73]. Binding of anti-Pr3 to Pr3
may interfere with the clearance of Pr3 released from neutrophils,
leading to the longer persistence of anti-Pr3-Pr3 complexes in
tissues. Subsequently, dissociation of active Pr3 from these com-
plexes contributes to tissue injury. Interestingly, disease activity of
Wegener’s granulomatosus correlated with the extent of inhibi-
tory activity of the antibodies on the inactivation of Pr3 by
a1-antitrypsin rather than with the anti-Pr3 titer itself [73, 74].
A HYPOTHETICAL MODEL FOR THE
PATHOPHYSIOLOGY OF ANCA ASSOCIATED VASCULITIS
Although many questions still remain, the experimental in vitro
data described above support the hypothesis that ANCA is more
than just a diagnostically useful epiphenomenon; it plays an
important role in the pathophysiology of their associated diseases.
The in vitro data also enable us to design a hypothetical model for
the pathophysiology of ANCA-associated vasculitis. Such a model
is depicted in Figure 1.
PATHOPHYSIOLOGICAL ROLE FOR ANCA IN VIVO
The relevance of the model proposed from in vitro studies for
the development of ANCA-associated vasculitis in vivo remains
speculative until an animal model for ANCA-associated diseases
has been developed, fulfilling Koch’s postulates [17]. Such an
animal model would allow the analysis of early events of the
disease process and the relative contribution and interaction of
different (immunological) components [75]. In addition, animal
models will be helpful in testing new therapeutic strategies. At
present, a fully satisfactory animal model for ANCA-associated
vasculitis has not been developed. During the last five years
several animal studies have, however, been reported on ANCA-
associated systemic or localized vasculitis, and are reviewed
below.
Anti-myoperoxidase antibodies in mercuric chloride-induced
vasculitis
Exposure to mercuric chloride (HgCl2) of susceptible rat
strains, usually of the Th2-responder type such as the Brown
Norway rat, induces an autoimmune syndrome mediated by T-cell
dependent polyclonal B-cell activation [76]. The HgCl2-induced
autoimmune syndrome is characterized by lymphoproliferation,
high IL-4 production, and hypergammaglobulinemia particularly
affecting the IgE class [77, 78]. In addition, a multitude of IgG
autoantibodies appear in this model including antibodies to DNA,
collagen, thyroglobulin and components of the glomerular base-
ment membrane (GBM) [79–82]. Antibodies to GBM compo-
nents are deposited in the kidney to produce linear to granular
staining of IgG along the GBM as shown by immunofluorescence
[80]. The deposition of anti-GBM antibodies is associated with the
development of proteinuria with only minor inflammatory
changes in the kidney [76, 79]. Anti-basement membrane antibod-
ies have also been demonstrated in tissues other than the kidneys,
but are not associated with tissue injury [83]. Similarly, no
histological evidence has been found for thyroid injury [79].
In 1992, Mathieson, Thiru and Oliveira described the occur-
rence of tissue injury in multiple organs in HgCl2-treated Brown
Norway rats [84]. In these studies, Brown Norway rats received
five subcutaneous injections of HgCl2 over a 10 day period and
autopsy studies were performed on days 10, 12, 16, and 18.
Histologically, tissue injury was observed in many organs includ-
ing the lungs, liver, skin, gut, and pancreas that increased in
severity over time. Subsequent studies showed that tissue injury
can be observed as early as 24 hours after the first injection of
HgCl2 and reaches its peak at two weeks [85]. In the lungs
interstitial pneumonitis and, occasionally, alveolar hemorrhage
were found. In the liver, abnormalities included portal lympho-
cytic infiltrates and, to a variable extent, fatty change in hepato-
cytes. Inflammatory changes were, however, most marked in the
duodenum and caecum, and were characterized by necrotizing
leukocytoclastic vasculitis of submucosal vessels accompanied by a
neutrophilic and mononuclear infiltrate. In the same study, it was
shown that pretreatment with broad spectrum antibiotics dimin-
ished HgCl2-induced vasculitis, although some mild perivascular
lymphocyte infiltration could still be observed [84]. This suggested
that the microbial load of the animals contributes to but is not
entirely responsible for HgCl2-induced vasculitis. Interestingly,
the same investigators showed that, in addition to the autoanti-
bodies described previously, HgCl2-treated Brown Norway rats
developed antibodies to MPO [86].
Subsequent studies in this experimental model have focused on
the cellular components and immunological mechanisms involved
in the development of tissue injury. These studies have demon-
strated an important role for autoreactive CD41 T-cells, which
upon transfer into healthy animals can induce the disease [87]. On
the other hand, it was shown that CD41OX22high T-cells are
protective against HgCl2-induced vasculitis since depletion of
these cells aggravates the severity of tissue injury, although the
autoantibody response was not affected [88]. Treatment with
cyclosporine during the early phase of the disease (that is, days 1
to 10) diminished tissue injury and delayed the rise in anti-MPO
and anti-GBM autoantibodies [89]. In contrast, when cyclosporine
was given late (days 11 to 14) a marked exarcebation of tissue
injury was observed, although the development of anti-MPO and
anti-GBM autoantibodies was completely suppressed [89]. Taken
together, these observations suggest that HgCl2-induced vasculitis
is primarily T-cell dependent. However, the rapid onset of tissue
injury, which can be observed as early as 24 hours after the first
injection of HgCl2, implicates that cells other than T-cells are
involved as well, especially during the induction phase of the
disease [85]. In this respect, an important role for mast cells has
been postulated [89]. Mast cells are abundantly present in the gut
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and, upon activation, release potent chemoattractants for neutro-
phils including TNFa and IL-8 [91, 92]. Indeed, mast cells can be
activated to release such inflammatory mediators after exposure
to HgCl2 [90]. In addition, depletion of circulating neutrophils by
monoclonal antibody treatment on days 10 to 14 significantly
reduced tissue injury, suggesting a crucial role for neutrophils in
the development of HgCl2-induced vasculitis [93].
Although the presence of anti-MPO antibodies has been clearly
demonstrated in HgCl2-exposed Brown Norway rats, their role in
the development of vasculitis is not known. Indirect evidence as
mentioned above suggests that anti-MPO antibodies are not
primarily involved in the pathogenesis of tissue injury. Also,
transfer of serum from HgCl2-treated Brown Norway rats into
normal Brown Norway rats failed to induce vasculitis [94].
In summary, the model of HgCl2-induced vasculitis has several
characteristics that resemble aspects of human systemic vasculitis.
First, as in humans, it features necrotizing vasculitis involving
small to medium sized vessels accompanied by fibrinoid necrosis
of the vessel wall and inflammatory cell infiltration. Second, there
is evidence that bacteria contribute to vascular injury in this
model. Third, autoantibodies, similar to those present in humans,
develop and their peak level coincides with maximal tissue injury.
Despite these analogies to human disease, the model also has
some important dissimilarities. In humans, necrotizing crescentic
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Fig. 1. Schematic representation of the immune mechanisms possibly involved in the pathophysiology of antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis. (1.) Cytokines released due to a (local) infection cause up-regulation of adhesion molecules on the endothelium and
priming of polymorphonuclear cells (PMN) and/or monocytes. (2.) Primed PMNs and/or monocytes express the ANCA antigens on the cell surface.
Adherence of primed PMNs and monocytes to the endothelium. (3.) Activation of primed PMNs/monocytes by ANCA induces the release of reactive
oxygen species and lysosomal enzymes leading to necrotizing inflammation potentiated by the inhibition by anti-proteinase 3 (Pr3) ANCA of the
a1-antitrypsin induced inactivation of Pr3. (4.) Induction of ANCA-mediated leukotriene B4 (LTB4) production by PMNs results in increased
production of reactive oxygen species (ROS) and degranulation and amplifies neutrophil influx. (5.) ANCA-induced monocyte chemoattractant
protein-1 (MCP-1) production amplifies monocyte recruitment possibly leading to granuloma formation. (6.) Binding of cationic myeloperoxidase
(MPO) or Pr3 released from (ANCA)-activated PMNs/monocytes to the endothelium or basement membranes leads to in situ immune complex
formation with complement activation. (7.) Expression of ANCA antigens in the context of MHC class II antigens may evoke delayed type
hypersensitivity reactions by autoreactive T-cells contributing to granuloma formation. (8.) Superantigen stimulation of B- and/or T-cells.
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glomerulonephritis is a prominent feature of ANCA-associated
vasculitis, but this is not observed in HgCl2-induced vasculitis. In
addition, since HgCl2 exposure induces the development of a wide
range of autoantibodies, it will be difficult to evaluate their
individual contribution to the induction of vasculitis. Although
indirect evidence suggests that anti-MPO are not primarily in-
volved in the development of tissue injury in this model, this has
not been proven unequivocally. In this respect, it is important to
note that the anti-MPO response in this model is usually tested in
ELISA systems using human MPO as the antigen, and there is no
information as to whether these antibodies also recognize rat
MPO and can activate rat neutrophils. Nevertheless, the model of
HgCl2-induced vasculitis has provided important information on
the cellular components involved in the development of vasculitis.
Spontaneous necrotizing vasculitis in MRL/lpr and SCG/Kj
mice
The MRL/lpr strain of mice has been used as an experimental
model for the study of systemic lupus erythematosus and rheu-
matoid arthritis [95, 96]. These mice spontaneously develop
lymphoproliferation, proliferative glomerulonephritis, and sys-
temic necrotizing vasculitis of small- and medium-sized arteries
and arterioles that particularly affect the kidney and gall bladder
[97, 98]. In the early stage of the disease, fibrinoid necrosis and
neutrophil influx are found, followed by a chronic infiltrate of
lymphocytes [97]. By immunofluoresence only scanty immune
complex deposits are observed in the kidney [97]. The spontane-
ous development of tissue injury in MRL/lpr mice is immunolog-
ically characterized by accumulation of T-cells with polyclonal
B-cell stimulation, resulting in the appearance of rheumatoid
factors and autoantibodies of diverse specificity including autoan-
tibodies directed against ds-DNA, ss-DNA, histones, and smooth
muscle cells [99, 100]. In addition, Harper, Lockwood and Cooke
reported that 20% of female MRL/lpr mice are positive for
ANCA [101]. However, monoclonal IgG antibodies derived from
these mice were found to be polyreactive, recognizing MPO,
lactoferrin and DNA [101].
The occurrence of vasculitis in many organs in MRL/lpr mice
has been attributed to a deficiency in apoptosis [102]. The lpr gene
is located on chromosome 19 and its product has been identified
as a protein belonging to the TNF/NGF receptor family known as
the Fas antigen [102, 103]. Since the Fas antigen is directly
involved in the pathway of apoptosis, it is now assumed that lpr
mice have a genomic deletion in parts of the Fas gene that results
in deficient apoptosis [102–104]. As a result, T-cells, which are
normally deleted by apoptosis, accumulate. Part of these T-cells
are autoreactive and may be involved in the induction of vasculitis.
In 1993, Kinjoh, Kyoguko and Good described a new recombi-
nant inbred strain of mice that spontaneously develops rapidly
progressive crescentic glomerulonephritis (CGN) and necrotizing
vasculitis; they are designated as spontaneous crescentic glomer-
ulonephritis (SCG) mice [105]. This strain of mice was established
from (BXSB 3 MRL/lpr) F1 hybrid mice by brother sister mating
of those mice whose parents had the highest frequency of crescent
formation. In the SCG/Kj mice, the incidence of spontaneous
crescentic glomerulonephritis (CGN) is as high as 58% in females
and 34% in males, and CGN is associated with extensive extra-
glomerular proliferation and hemorrhage in the Bowman’s space.
By immunofluorescence, only scanty deposits of immunoglobulins
and complement are found along the glomerular basement mem-
brane. In addition to CGN, necrotizing vasculitis of small and
medium sized arteries and arterioles is observed in many organs
including the spleen, ovary, uterus, heart, and stomach. However,
in contrast to MRL/lpr mice, necrotizing vasculitis is not found in
the kidneys. Serum from SCG/Kj mice produce a perinuclear
ANCA (P-ANCA) staining pattern on human and murine neu-
trophils and react with a murine neutrophil extract and human
MPO by ELISA [106]. Transfer of MPO specific hybridomas
derived from SCG/Kj mice into the peritoneum of nude mice
induced proteinuria, although histologically no evidence for glo-
merulonephritis or vasculitis was found [107].
The spontaneous nature of the disease in a mouse model
developed by selective genetic breeding is clearly an advantage,
and these models are useful for identifying genes that determine
susceptibility for the development of vasculitis. In addition, the
introduction (transgene) or deletion (knockout) of genes of
interest by recombinant DNA technology in vasculitis prone mice
could provide important information on the involvement of
specific proteins in the development of vasculitis in these mice.
However, with regard to ANCA-associated vasculitis, such models
are hampered by the polyclonal nature of the autoantibody
response. This will render it difficult to define the pathophysio-
logical role of any of these autoantibodies in the development of
vasculitis and glomerulonephritis.
In this respect, a novel recombinant congenic strain of mice,
designated McH5-lpr/lpr, has recently been established by hybrid-
ization of MRL/lpr mice with C3H/HeJ-lpr/lpr mice, which are not
prone to the development of autoimmune disease [108]. McH5-
lpr/lpr mice spontaneously develop severe granulomatous arteritis
especially affecting the kidney. In contrast to MRL/lpr mice, the
incidence of glomerulonephritis is low (8.3% vs. 98.2% for
McH5-lpr/lpr mice and MRL/lpr mice, respectively). Interestingly,
this low frequency of glomerulonephritis is associated with a
significant reduction in anti-MPO and anti-DNA autoantibody
titers, but not of rheumatoid factors. These studies suggest that
different pathogenic mechanisms underlie the development of
arteritis and glomerulonephritis. Indirectly, they also suggest that
anti-MPO and anti-DNA antibodies are not involved in the
development of arteritis but may be of pathogenic importance for
the induction of glomerulonephritis.
Glomerulonephritis and vasculitis in myeloperoxidase-
immunized rats
As discussed before, the ANCA antigens MPO and proteinase
3 are constituents of neutrophil azurophilic granules and mono-
cyte lysosomes, which, upon activation of neutrophils and mono-
cytes, are released into the extracellular environment. Because of
their cationic nature, these enzymes will then readily bind to
anionic structures such as basal membranes and/or endothelial
cells. In this way, MPO and Pr3 can serve as planted antigens to
which ANCA will bind. Hypothetically, the formation of such
focal immune complexes may enhance the inflammatory process
by complement activation, increased influx of inflammatory cells
and antibody-dependent cellular cytotoxicity. Based on this hy-
pothesis, our group developed an animal model for anti-MPO
associated necrotizing crescentic glomerulonephritis (NCGN)
[109]. In this model, Brown Norway rats were immunized with
human MPO leading to the development of anti-human MPO
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antibodies cross reacting with rat MPO and delayed-type hyper-
sensitivity to human MPO. Subsequently, unilateral perfusion of
the left kidney was performed with products of activated neutro-
phils consisting of proteolytic enzymes (elastase and proteinase 3),
MPO and its substrate H2O2 (Fig. 2). In contrast to control
immunized rats, MPO-immunized rats developed severe NCGN
with interstitial infiltrates and vasculitis (Fig. 3). In this model,
MPO, IgG and C3 are present along the GBM at 24 hours after
perfusion. However, at 4 and 10 days after perfusion these
immune deposits were generally absent. These studies demon-
strate that ANCA-associated NCGN probably develops after focal
immune complex formation along the GBM. Degradation of these
immune complexes by proteolytic enzymes released from acti-
vated neutrophils could be responsible for the pauci-immune
character of the lesions.
Since focal fibrinoid necrosis of capillary loops is found in the
very early stages of ANCA-associated NCGN, it is suggested that
renal ischemia plays an additional role in its pathophysiology.
Brouwer et al tested this hypothesis in their rat model by
introducing ischemia reperfusion injury through clamping of the
renal artery after perfusion of the lysosomal extract (Fig. 2) [110].
These studies showed that clamp ischemia can replace perfusion
with H2O2 in this experimental model of anti-MPO-associated
NCGN. Furthermore, renal ischemia seems to contribute to the
development of anti-MPO-associated NCGN through induction
of the production of reactive oxygen metabolites production by
endothelial cells [110].
The studies of Brouwer et al have been repeated by Yang,
Jennette and Falk in both BN rats and spontaneously hypertensive
rats [111]. They showed that in the latter rats more severe lesions
develop illustrating the additive effect of hypertension. However,
immune deposits could still be observed in the latter model at 10
days after perfusion in both rat strains [111]. Differences in the
immunization procedure and the composition of the neutrophil
lysosomal extract may explain these conflicting results.
In most cases of ANCA-associated vasculitis, vascular lesions
are not confined to the kidneys but can affect almost any organ.
Our group recently addressed the question whether systemic
injection of products of activated neutrophils in MPO-immunized
Brown Norway rats would lead to systemic vasculitis (Fig. 2) [112].
It was shown that upon systemic injection of a neutrophil lysoso-
mal extract and H2O2 MPO-immunized BN rats develop a
necrotizing vasculitis in the lungs and gut (Fig. 3). Such vasculitic
changes were not found in control immunized rats. Although no
inflammatory lesions were observed in the kidney, these studies
extend the observations of Brouwer et al by showing the devel-
opment of vasculitis in lungs and gut depending on the presence
of anti-MPO antibodies and the administration of active neutro-
phil lysosomal enzymes.
In line with the above-mentioned findings are the studies of
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Fig. 2. Schematic representation of the animal models for anti-myeloperoxidase (MPO) associated vasculitis based on immunization of Brown Norway
rats with human MPO. Upon immunization of human MPO, these rats develop antibodies to human MPO which cross react with rat MPO. (1.)
Unilateral renal perfusion of a polymorphonuclear cell (PMN) lysosomal extract and H2O2 in MPO-immunized rats leads to necrotizing crescentic
glomerulonephritis. (2.) Unilateral renal perfusion of a PMN lysosomal extract without H2O2 followed by clamp ischemia in MPO-immunized rats also
leads to necrotizing crescentic glomerulonephritis. (3.) Systemic injection of a PMN lysosomal extract and H2O2 in MPO-immunized rats leads to
necrotizing vasculitis in the lungs and gut but not in the kidneys. (4.) Subnephritogenic anti-GBM disease is aggravated in MPO-immunized rats.
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Kobayashi, Shibata and Sugisaki showing that anti-GBM nephritis
in rats is aggravated by the administration of heterologous rabbit
anti-rat MPO antibodies [113]. The administration of rabbit
anti-rat MPO antibodies together with rabbit anti-rat GBM
antibodies resulted in an increased influx of neutrophils and more
extensive fibrin depositions compared with rats injected with
normal rabbit antibodies and rabbit anti-rat GBM antibodies. Rat
MPO was detected along the GBM and rabbit anti-rat MPO
antibodies could be eluted from the kidneys. No evidence, how-
ever, was found for crescent formation and vasculitis. These
studies suggest the direct involvement of anti-MPO antibodies in
the development of glomerulonephritis either by in situ immune
complex formation or direct activation of infiltrated polymorpho-
nuclear cells (PMNs).
Recently, our group demonstrated aggravation of subnephrito-
genic anti-GBM nephritis in Brown Norway rats previously im-
munized with human MPO [114]. Upon immunization with
human MPO rats not only developed antibodies to human MPO,
but to rat MPO as well. Following injection of a subnephritogenic
dose of rabbit anti-rat GBM antibodies, severe glomerulonephri-
tis developed characterized by the early occurrence of hematuria
and severe proteinuria at day 10 (Fig. 2). In this model, MPO-
immunized rats developed renal lesions characterized by fibrinoid
necrosis of glomerular capillaries, extensive fibrin deposition,
interstitial and intraglomerular accumulation of monocytes/mac-
rophages and crescent formation (Fig. 3). In addition, extracellu-
lar granular depositions of rat MPO were observed in glomeruli
confirming the data of Kobayashi et al. In control immunized rats
injected with the anti-GBM antibodies only mild glomerulone-
phritis was found without evidence for crescent formation, sug-
gesting that the autologous anti-rat MPO antibodies are respon-
sible for the exacerbation of the anti-GBM disease in this model.
The studies described above all support the hypothesis that the
presence of ANCA in itself is not sufficient to cause tissue injury.
Additional factors inducing a (pro)-inflammatory environment
are needed which initially result in priming of neutrophils and
monocytes and activation of the endothelium. Next, ANCA
activate primed neutrophils/monocytes and form in situ immune
complexes with ANCA antigens released from activated neutro-
phils, thereby exacerbating the inflammatory response, finally
leading to vasculitis and tissue destruction.
A mouse model for Wegener’s granulomatosis induced by
idiotypic manipulation
It has been postulated that activation of the idiotypic network
causing dysregulation of the immune system underlies the induc-
tion of autoimmune diseases such as systemic lupus erythemato-
sus (SLE) and scleroderma, and also Wegener’s granulomatosis
[115]. In this theory, it is assumed that during bacterial or viral
infections antibodies are generated directed against bacterial or
viral antigens containing pathogenic, that is, autoimmune, idio-
types (ab1). The presence of such pathogenic idiotypes in concert
with the adjuvant effect of the bacterial infection may initiate an
idiotypic cascade leading to the generation of anti-idiotype (ab2)
and anti-anti-idiotype antibodies (ab3). The latter antibody (ab3)
is similar to the pathogenic idiotype (ab1) in its specificity and may
eventually lead to autoimmune manifestations [115, 116].
The idiopathic dysregulation theory has been the basis for the
induction of experimental models for several autoimmune dis-
eases including SLE, antiphospholipid syndrome, and Wegener’s
granulomatosis [117–120]. In these models, mice are actively
immunized with a pathogenic autoantibody derived from patients
with the respective autoimmune disease. For the Wegener’s
Fig. 3. Light micrographs illustrating the histopathological findings in
the animal models for anti-myeloperoxidase (MPO) associated vasculitis
described in Figure 2. (1.) Glomerular crescent formation, gaps in
Bowman’s capsule and periglomerular infiltration in a MPO-immunized
rat four days after unilateral perfusion of a polymorphonuclear cell
(PMN) lysosomal extract and H2O2 (MS staining 3100). (2.) Formation of
multinucleated giant cells and tissue necrosis with nuclear debris in the
lungs of a MPO-immunized rat seven days after systemic injection of a
PMN lysosomal extract and H2O2 (PAS staining 3100). (3.) Glomerular
crescent formation and tuft necrosis 10 days after injection of a subne-
phritogenic dose of rabbit anti-rat GBM antibodies in a MPO-immunized
rat (MS staining 3100).
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granulomatosis model, affinity-purified Pr3-IgG derived from two
separate Wegener’s granulomatosis patients was used for immu-
nization [120]. After two weeks, mice developed anti-idiotypic
(mouse anti-human anti-Pr3 antibodies, ab2) and after four
months anti-anti-idiotypic antibodies reacting with human Pr3
(ab3). In addition, sera derived from these mice also reacted with
human MPO and endothelial surface proteins. Histopathologi-
cally, sterile microabcesses developed in the lungs after eight
months and mice died between 8 and 15 months after immuniza-
tion with the Wegener’s granulomatosis IgG. In a second exper-
iment using affinity-purified Pr3-IgG from another Wegener’s
granulomatosis patient, the same autoantibodies could be de-
tected but histopathologically no abscesses were observed in the
lungs and mice survived until the time of sacrifice. To further
substantiate the pathogenic potential of the mouse anti-Pr3
antibodies (ab3), the antibodies were tested for their neutrophil
activating ability [121] showing that these antibodies are capable
of inducing adhesion of human neutrophils to fibronectin and
initiating a respiratory burst. It is, however, not clear from these
experiments whether the antibodies also recognize murine Pr3.
This would be an essential step in proving that they have
pathogenic potential in this model.
The studies described above demonstrate that dysregulation of
the idiotypic network may lead to the development of pathogenic
autoantibodies. Whether this theory is relevant for the induction
of ANCA-associated vasculitis is, however, not proven until
pathogenic idiotypes on bacterial or viral antigens are identified.
CONCLUSION
The significance of ANCA as diagnostic markers for systemic
necrotizing vasculitis or idiopathic necrotizing crescentic glomer-
ulonephritis is well established. Detection of anti-Pr3 autoanti-
bodies strongly suggests a diagnosis of Wegener’s granulomatosis,
and changes in serum levels of anti-Pr3 autoantibodies seem to
mirror disease activity. Anti-myeloperoxidase autoantibodies are
associated with various forms of systemic necrotizing vasculitis
including idiopathic necrotizing crescentic glomerulonephritis.
Their usefulness in measuring disease activity is at present not
clear, although some studies suggest that rises in anti-MPO levels
precede relapses.
Many questions remain concerning the pathophysiological role
of ANCA. In vitro studies have shown that ANCA activate
cytokine-primed neutrophils and monocytes leading to the release
of lysosomal enzymes and the production of reactive oxygen
species (ROS) and cytokines. Interaction of ANCA with their
target antigens bound to the endothelium aggravates the inflam-
matory process. Moreover, anti-Pr3 antibodies interfere with the
inactivation of proteinase 3 by a1-antitrypsin. All these effects
potentially contribute to vascular injury, but whether these phe-
nomena are also operative in vivo is not clear.
The in vivo models for ANCA-associated diseases described
above suggest, but do not definitely prove, that ANCA are
pathogenic. None of the models completely mirrors the human
counterpart as is often the case with experimental models [75].
One important observation from the in vivo models is that ANCA
in itself are not pathogenic, as anti-MPO antibodies, which either
occur as part of a polyclonal B-cell response or induced by active
immunization, do not cause disease manifestations. Additional
factors inducing priming or activation of neutrophils and mono-
cytes are required. As such the in vivo models mirror the situation
in humans in which high levels of ANCA can be present without
signs of disease activity. Therefore, future in vivo studies should be
aimed at elucidating the initial factors triggering ANCA-associ-
ated vasculitis. The clinical observation showing chronic nasal
carriage of Staphylococcus aureus as a risk factor for relapses in
Wegener’s granulomatosis suggests that Staphylococcus aureus or
components thereof are attractive candidates.
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APPENDIX
Abbreviations used in this article are: ANCA, anti-neutrophil cytoplas-
mic antibodies; NCGN, nectorizing crescentic glomerulonephritis; Pr3,
proteinase 3; MPO, myeloperoxidase; TNFa, tumor necrosis factor alpha;
ROI, reactive oxygen intermediates; ROS, reactive oxygen species; IFNg,
interferon gamma; IL-1B, interleukin-1beta; ADCC, antibody-dependent
cellular cytotoxicity; PMNs, polymorphonuclear cells; GBM, glomerular
basement membrane; SCG, spontaneous crescentic glomerulonephritis;
ab1, pathogenic idiotype antibody; ab2, anti-idiotype antibody; ab3, anti-
anti-idiotype antibody; SLE, systemic lupus erythematosus.
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